谢纬运用中医药联合靶向药物治疗ALK阳性肺腺癌验案一则
Treatment of ALK Positive Lung Adenocarcinoma with Traditional Chinese Medicine and Targeted Drugs: A Case Report
扫 描 看 全 文
1.广州中医药大学第四临床医学院,深圳 518033
2.深圳市中医院呼吸与危重症医学科,深圳 518033
扫 描 看 全 文
叶景焕, 陈珠妮, 谢纬. 谢纬运用中医药联合靶向药物治疗ALK阳性肺腺癌验案一则[DB/OL].(2023-10-27)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=43166829&Fpath=home&index=0
YE Jinghuan, CHEN Zhuni, XIE Wei. Treatment of ALK Positive Lung Adenocarcinoma with Traditional Chinese Medicine and Targeted Drugs: A Case Report[DB/OL].(2023-10-27)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=43166829&Fpath=home&index=0
叶景焕, 陈珠妮, 谢纬. 谢纬运用中医药联合靶向药物治疗ALK阳性肺腺癌验案一则[DB/OL].(2023-10-27)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=43166829&Fpath=home&index=0 DOI:
YE Jinghuan, CHEN Zhuni, XIE Wei. Treatment of ALK Positive Lung Adenocarcinoma with Traditional Chinese Medicine and Targeted Drugs: A Case Report[DB/OL].(2023-10-27)[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=43166829&Fpath=home&index=0 DOI:
病史摘要,2,患者彭某,女性,27岁,2019年8月27日因“肺腺癌靶向药物治疗后恶心呕吐、头痛1月余”就诊。2018年7月22日患者因“发热、咳嗽、左胸背疼痛”就诊于深圳市中医院呼吸与危重症医学科,被诊断为“左肺浸润性腺癌、ALK阳性”,予靶向药阿来替尼治疗1年后出现恶心呕吐、头痛等不适症状,故来我院门诊就诊。四诊信息:患者咳嗽、咳少量白痰,肩背痛,偶有胸闷,恶心呕吐,神疲乏力,面色苍白,恶寒喜暖,鼻塞流涕,鼻涕倒流,口干、无口苦,双手掌皮肤甲错潮红,纳差,寐差,大便干结,夜尿多。舌质红、苔少,脉细弱。中医诊断 肺积(痰毒瘀结,气阴两虚证)。西医诊断 左肺下叶恶性肿瘤(肺腺癌、ALK阳性)。干预措施 中医治疗以益气养阴,化痰散结为法,予益气养阴方加减治疗;西医治疗予靶向药阿来替尼口服治疗。疗效转归 患者服靶向药物恶心呕吐未再发作,咳嗽咳痰、肩背痛等未再发作,睡眠佳。门诊随访患者病情稳定,未见肿瘤复发迹象。
Summary of case history, The patient Peng, female, 27 years old, went to the doctor on August 27, 2019 due to "nausea and vomiting after targeted drug therapy for lung adenocarcinoma, and headache for more than 1 month". On July 22, 2018, the patient was diagnosed with "infiltrating adenocarcinoma of the left lung, positive for ALK" in the Department of Respiratory and Critical Care Medicine of Shenzhen Hospital of Traditional Chinese Medicine due to "fever, cough, and pain in the left chest and back". After 1 year of treatment with letinib, nausea, vomiting, headache and other discomfort symptoms occurred, so he came to our hospital for outpatient treatment. Symptoms and signs: the patient coughed, coughed up a small amount of white sputum, shoulder and back pain, occasional chest tightness, nausea and vomiting, fatigue, pale complexion, aversion to cold and warmth, stuffy nose, runny nose, dry mouth, no bitter mouth, double the skin on the palms is flushed, poor appetite, poor sleepiness, dry stools, and frequent urination at night. Red tongue, little fur, thready and weak pulse.,TCM diagnosis, Lung accumulation(phlegm toxin stasis syndrome of deficiency of both qi and yin).,Western medicine diagnosis, left lower lobe malignant tumor (cT1N2M1c IV, ALK positive),.Therapeutic methods, The traditional Chinese medicine treatment is based on replenishing qi and nourishing yin, resolving phlegm and dispelling stagnation, and is treated with modified formulas for nourishing qi and nourishing yin; western medicine treats with targeted drug alectinib orally.,Clinical outcomes, Nausea and vomiting did not reoccur after the patient took targeted drugs, cough and sputum, shoulder and back pain did not recur, and sleep was good. The patient's condition was stable during outpatient follow-up, and no signs of tumor recurrence were found.
肺腺癌靶向药物肺积痰毒瘀结气阴两伤晁恩祥
Lung adenocarcinomatargeted drugsLung accumulationphlegm-toxin stagnationQi-Yin injuryEnxiang Chao
宋勇,杨雯. 2014 年晚期非小细胞肺癌内科治疗进展[J].解放军医学杂志, 2015, 40(1):10-15.
ZHENG RS, SUN KX, ZHANG SW, et al. Report of cancer epidemiology in China, 2015[J]. Chin J Oncol, 2019, 41(1):19-28.
SIEGEL RL, MILLER KD, JEMAL A. Cancer Statistics, 2017[J].CA Cancer J Clin, 2017, 67(1):7-30.
赵英玲,罗玲,叶春桃,等.间变性淋巴瘤激酶抑制剂治疗肿瘤研究回顾[J].中医药临床杂志,2020,32(9):1610-1614.
许银姬,王辛秋,晁恩祥.国医大师晁恩祥教授治疗肺癌临证经验拾萃[J].新中医,2016,48(8):228-229.
郑淑君,王辛秋,贾喜花,等.国医大师晁恩祥辨治肺癌经验[J].中华中医药杂志,2022,37(7):3855-3857.
贾元萍,张洪春,田传玺,等.晁恩祥运用养阴益气法治疗肺癌发热经验[J].中医杂志,2021,62(22):1952-1955.
Peters S, Camidge DR, Shaw AT, et al. ALEX Trial Investigators. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017, 377(9):829-838.
Zhou C, Lu Y, Kim SW, et al. Primary results of ALESIA: A randomised, phase Ⅲ, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC[J]. Ann Oncol, 2018, 29(Supplement 8). doi:https://doi.org/10.1093/annonc/mdy424.062https://doi.org/10.1093/annonc/mdy424.062.
Gainor JF, Shaw AT. J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer. Lancet. 2017, 390(10089):3-4.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构